Early Experience with Intensity Modulated Proton Therapy for Lung-intact Mesothelioma: A Case Series
Overview
Authors
Affiliations
Purpose: The purpose of this study was to describe our experience implementing intensity modulated proton therapy (IMPT) for lung-intact malignant pleural mesothelioma (MPM), including patient selection, treatment planning, dose verification, and process optimization.
Methods And Materials: Seven patients with epithelioid MPM were reviewed; 6 underwent pleurectomy, whereas 1 had biopsy alone. Four patients received IMPT and 3 received intensity modulated radiation therapy. Treatment plans for the other modality were created for dosimetric comparisons. Quality assurance processes included dose verification and robustness analysis. Image-guided setup was performed with the first isocenter, and couch shifts were applied to reposition to the second isocenter.
Results: Treatment with IMPT was well tolerated and completed without breaks. IMPT plans were designed with 2 isocenters, 4 beams, and ≤64 energy layers per beam. Dose verification processes were completed in 3 hours. Total daily treatment time was approximately 45 minutes (20 minutes for setup and 25 minutes for delivery). IMPT produced lower mean doses to the contralateral lung, heart, esophagus, liver, and ipsilateral kidney, with increased contralateral lung sparing when mediastinal boost was required for nodal disease.
Conclusions: Our initial experience showed that IMPT was feasible for routine care of patients with lung-intact MPM.
Franceschini D, Cozzi L, Fogliata A, Marini B, Di Cristina L, Dominici L Radiat Oncol. 2022; 17(1):150.
PMID: 36028862 PMC: 9419376. DOI: 10.1186/s13014-022-02119-x.
Moore A, Kindler M, Allen A Biology (Basel). 2021; 10(8).
PMID: 34439944 PMC: 8389276. DOI: 10.3390/biology10080711.
New horizons from novel therapies in malignant pleural mesothelioma.
Sayan M, Mamidanna S, Eren M, Daliparty V, Mustafayev T, Nelson C Adv Respir Med. 2020; 88(4):343-351.
PMID: 32869268 PMC: 10865433. DOI: 10.5603/ARM.a2020.0103.
Malignant Pleural Mesothelioma: State-of-the-Art on Current Therapies and Promises for the Future.
Nicolini F, Bocchini M, Bronte G, Delmonte A, Guidoboni M, Crino L Front Oncol. 2020; 9:1519.
PMID: 32039010 PMC: 6992646. DOI: 10.3389/fonc.2019.01519.
Pehlivan B, Sengul K, Yesil A, Nalbant N, Ozturk O, Ozdemir Y Biomed Res Int. 2020; 2019:4568958.
PMID: 31930123 PMC: 6942749. DOI: 10.1155/2019/4568958.